CEL-SCI Announces Closing of Offering

Source Summary

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $2.5 million.